Clinic Roundup
Collegium Pharmaceutical Inc., of Cumberland, R.I., said it started enrollment in a Phase III study of Oxycodone DETERx (COL-003), a tamper-resistant, extended-release version of oxycodone.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.